Image-guided radiation therapy developer ViewRay launched a multicenter prospective clinical trial using MRIdian for locally advanced unresectable pancreatic cancer.
The study is the first initiative of ViewRay's Clinical Cooperative Think Tank (C2T2), a group of MRIdian clinical users focused on evidence gathering to support MR-guided radiation therapy. The trial will study MRIdian's capabilities and associated toxicity, local control, and patient outcomes regarding locally advanced unresectable pancreatic cancer, the company said.
